Who are rizatriptan benzoate (MK0462)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ALMOTRIPTAN MALATE, conventional migraine drug treatment, almotriptan or pseudoephedrine, Sumatriptan and Naproxen sodium, Triptans, Rizatriptan co-administered with Acetaminophen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rizatriptan-benzoate-mk0462.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

rizatriptan benzoate (MK0462) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

rizatriptan benzoate (MK0462) (rizatriptan benzoate (MK0462)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin receptor agonist. Area: Neurology.

phase 3 Serotonin receptor agonist 5-HT1B/1D receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

rizatriptan benzoate (MK0462) (rizatriptan benzoate (MK0462)) — Organon and Co. Rizatriptan benzoate is a selective serotonin 5-HT1B/1D receptor agonist, which is believed to relieve migraine headaches by causing vasoconstriction and inhibiting pro-inflammatory neuropeptide release.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
rizatriptan benzoate (MK0462) TARGET	rizatriptan benzoate (MK0462)	Organon and Co	phase 3	Serotonin receptor agonist	5-HT1B/1D receptor
ALMOTRIPTAN MALATE	ALMOTRIPTAN MALATE		marketed	Triptan	5-HT1B/1D receptors	2001-01-01
conventional migraine drug treatment	conventional migraine drug treatment	Birjand University of Medical Sciences	marketed	Triptan, ergot alkaloid, or NSAID (class varies by specific agent)	5-HT1B/1D receptors (triptans); COX inhibition (NSAIDs); or alpha-adrenergic/serotonergic receptors (ergots)
almotriptan or pseudoephedrine	almotriptan or pseudoephedrine	Clinvest	marketed	Triptan + sympathomimetic decongestant combination	5-HT1B/1D receptors (almotriptan); alpha-adrenergic receptors (pseudoephedrine)
Sumatriptan and Naproxen sodium	Sumatriptan and Naproxen sodium	POZEN	marketed	Triptan/NSAID combination	5-HT1B/1D receptors (sumatriptan); COX-1/COX-2 (naproxen sodium)
Triptans	triptans	Pfizer	marketed	Selective serotonin receptor agonists	Serotonin 5-HT1B/1D receptors
Rizatriptan co-administered with Acetaminophen	Rizatriptan co-administered with Acetaminophen	Diamond Headache Clinic	phase 3	Triptan + analgesic combination	5-HT1B/1D receptor (rizatriptan); COX inhibitor (acetaminophen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin receptor agonist class)

Addpharma Inc. · 1 drug in this class
Organon and Co · 1 drug in this class
Serenity Pharmaceuticals, Inc. · 1 drug in this class
University Hospital, Strasbourg, France · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rizatriptan benzoate (MK0462) — Competitive Intelligence Brief. https://druglandscape.com/ci/rizatriptan-benzoate-mk0462. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing